Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
43 Leser
Artikel bewerten:
(0)

Young Innovations, Inc. Announces Record Sales and EPS for the Nine-Months Ended September 30, 2012 and Declares Quarterly Dividend

ST. LOUIS, Oct. 23, 2012 /PRNewswire/ -- Young Innovations, Inc. (NASDAQ - YDNT) today announced record sales and earnings per share for the nine-months ended September 30, 2012.

Sales for the third quarter of 2012 were $27.1 million, an increase of 3.5% from the $26.2 million reported for the third quarter of 2011. Income from operations for the third quarter increased 6.0% to $6.6 million from $6.3 million in the prior year quarter. Net income for the third quarter increased 4.8% to $4.3 million from $4.1 million in the third quarter of 2011. Diluted earnings per share for the third quarter of 2012 were $0.54, an increase of 5.9% over the $0.51 reported in the prior year quarter. Diluted earnings per share were affected by equity compensation expense of $0.04 in both the third quarter of 2012 and 2011. Diluted shares outstanding were 7.9 million for the third quarter of 2012, down 1.6% from 8.0 million in the prior year quarter.

For the nine months ended September 30, 2012 sales were $81.9 million, increasing 3.0% from the $79.5 million reported in the prior year period. Income from operations increased 5.7% to $19.3 million for the nine months ended September 30, 2012 from $18.2 million in the prior year period. Net income was $12.9 million for the nine months ended September 30, 2012, increasing 6.3% from $12.1 million in the prior year period. Diluted earnings per share were $1.63 for the nine months ended September 30, 2012, an increase of 7.9% from $1.51 in the prior year period. Diluted earnings per share were affected by equity compensation expense of $0.12 for both the nine months ended September 30, 2012 and 2011. Diluted shares outstanding for the nine months ended September 30, 2012 decreased 0.3% to 7.9 million from the prior year period.

We are pleased with the Company's overall performance during the quarter. We experienced healthy demand for our consumable products and strong growth in sales of our diagnostic product line. Third quarter sales were also positively impacted by product introductions from the first half of 2012.

We remained focused on executing our strategy for growth during the quarter. We launched a new line of preventive prophylaxis products and made significant progress on other new product introductions. We continued to invest in new capital equipment at several of our facilities to support new product development and increase production capacity and efficiency. Finally, we successfully executed new marketing, merchandising and promotional strategies that helped build brand awareness across several of our product lines.

Although we remain cautious about the overall economic environment as we begin the fourth quarter, we remain optimistic about the Company's ability to take advantage of the opportunities for growth we see before us.

The company also announced that on October 23, 2012 the Board of Directors declared a quarterly dividend of $0.04 per share, payable on December 14, 2012 to all shareholders of record on November 15, 2012.

A conference call has been scheduled for Wednesday, October 24, 2012 at 11:00 A.M. Central Time and can be accessed through InterCall at http://tinyurl.com/YI-Quarter32012 or the Company's website, www.ydnt.com.

Young Innovations develops, manufactures and markets supplies and equipment used by dentists, dental hygienists, dental assistants and consumers. The Company's consumables product offering includes disposable and metal prophy angles, prophy cups and brushes, dental micro-applicators, moisture control products, infection control products, dental handpieces (drills) and related components, endodontic systems, orthodontic toothbrushes, flavored examination gloves, children's toothbrushes, and children's toothpastes. In addition, the Company offers a line of diagnostic products that includes panoramic X-ray machines and related supplies. The Company believes it is a leading U.S. manufacturer or distributor of prophy angles and cups, liquid surface disinfectants, dental micro-applicators and obturation units designed for warm, vertical condensation.

Investors are cautioned that this press release as well as other reports and oral statements by Company officials may contain certain forward-looking statements as defined in the Private Securities Litigation and Reform Act of 1995. Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions and which include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," or similar expressions. These statements are not guarantees of future performance and the Company makes no commitment to update or disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements. Because such statements involve risks and uncertainties, actual actions and strategies and the timing and expected results thereof may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, those disclosed in the Company's Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission.

Young Innovations, Inc.

Consolidated Statements of Income

(In thousands, except earnings per share data)

(Unaudited)

(In Thousands USD)












Three Months Ended



Nine Months Ended



September 30,



September 30,



2012


2011

Change


2012


2011

Change











Net Sales

$ 27,123


$ 26,197

3.5%


$ 81,931


$ 79,548

3.0%

Cost of Goods Sold

$ 12,097


$ 11,585

4.4%


$ 36,311


$ 35,325

2.8%

Gross Profit

$ 15,026


$ 14,612

2.8%


$ 45,620


$ 44,223

3.2%

% of Net Sales

55.4%


55.8%



55.7%


55.6%












Selling, General and Administrative Expense

$ 8,395


$ 8,359

0.4%


$ 26,354


$ 26,000

1.4%

% of Net Sales

31.0%


31.9%



32.2%


32.7%












Income from Operations

6,631


6,253

6.0%


19,266


18,223

5.7%

% of Net Sales

24.4%


23.9%



23.5%


22.9%












Interest expense, net

(59)


(49)



(172)


(177)


Other income (expense), net

7


100



749


568












Income Before Taxes

6,579


6,304

4.4%


19,843


18,614

6.6%











Provision for Income Taxes

2,282


2,204



6,945


6,477












Net Income

$ 4,297


$ 4,100

4.8%


$ 12,898


$ 12,137

6.3%

% of Net Sales

15.8%


15.7%



15.7%


15.3%












Basic Earnings Per Share

$ 0.54


$ 0.51

5.9%


$ 1.63


$ 1.51

7.9%











Basic Weighted Average Shares Outstanding

7,905


8,018



7,887


8,013












Earnings Per Share (Diluted)

$ 0.54


$ 0.51

5.9%


$ 1.63


$ 1.51

7.9%











Diluted Weighted Average Shares Outstanding

7,914


8,041



7,891


8,065












YI Consolidated


Consolidated Balance Sheet


September 30, 2012 and December 31, 2011


(In Thousands USD)








(Unaudited)








September 30


December 31



Assets


2012


2011



Current assets








Cash


$ 15,038


$ 1,031




Accounts receivable, net


13,004


12,066




Inventories


17,625


17,161




Other current assets


4,676


4,729



Total current assets


50,343


34,987











Property, plant and equipment, net


31,134


32,272



Goodwill


80,248


80,254



Intangible assets


10,817


11,130



Other assets


813


1,143











Total assets


$ 173,355


$ 159,786











Liabilities and Equity







Current liabilities








Accounts payable and accrued liabilities


$ 10,470


$ 9,134



Total current liabilities


10,470


9,134











Long-term debt


-


650



Long-term secured borrowing


-


9



Deferred income taxes


19,374


19,534



Other noncurrent liabilities


202


206



Total liabilities


30,046


29,533











Stockholders' equity








Common stock


102


102




Additional paid-in capital


25,643


24,708




Retained earnings


170,601


158,647




Common stock in treasury, at cost


(52,750)


(52,924)




Accumulated other comprehensive (loss)


(287)


(280)



Total stockholders' equity


143,309


130,253











Total liabilities and stockholders' equity


$ 173,355


$ 159,786











SOURCE Young Innovations, Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.